Search

Your search keyword '"Schroeder, Heather M."' showing total 25 results
Start Over Author "Schroeder, Heather M."
25 results on '"Schroeder, Heather M."'

12. Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Author

Short, Nicholas J., primary, Kantarjian, Hagop, additional, Ravandi, Farhad, additional, Huang, Xuelin, additional, Thompson, Philip A., additional, Ferrajoli, Alessandra, additional, Kadia, Tapan M., additional, Jain, Nitin, additional, Alvarado, Yesid, additional, Yilmaz, Musa, additional, Khoury, Joseph D., additional, Jorgensen, Jeffrey L., additional, Wang, Sa A, additional, Kornblau, Steven M., additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Garris, Rebecca, additional, Schroeder, Heather M, additional, Milton, Anna, additional, Rivera, Juan, additional, Banks, Glenda, additional, and Jabbour, Elias J., additional

Published
2021
Full Text
View/download PDF

13. Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis

Author

Sasaki, Koji, primary, Kantarjian, Hagop M., additional, Morita, Kiyomi, additional, Short, Nicholas J., additional, Konopleva, Marina, additional, Jain, Nitin, additional, Ravandi, Farhad, additional, Garcia‐Manero, Guillermo, additional, Wang, Sa, additional, Khoury, Joseph D., additional, Jorgensen, Jeffrey L., additional, Champlin, Richard E., additional, Khouri, Issa F., additional, Kebriaei, Partow, additional, Schroeder, Heather M., additional, Khouri, Maria, additional, Garris, Rebecca, additional, Takahashi, Koichi, additional, O’Brien, Susan M., additional, and Jabbour, Elias J., additional

Published
2021
Full Text
View/download PDF

14. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Author

Short, Nicholas J., Kantarjian, Hagop M., Ravandi, Farhad, Huang, Xuelin, Ferrajoli, Alessandra, Kadia, Tapan M., Thompson, Philip A., Alvarado, Yesid, Jain, Nitin, Yilmaz, Musa, Khoury, Joseph D., Jorgensen, Jeffrey L., Wang, Sa A, Kornblau, Steven M., Konopleva, Marina, Garcia-Manero, Guillermo, Schroeder, Heather M, Kwari, Monica, Paul, Shilpa, Nwakanme, Benjamin, Loiselle, Christopher, Garris, Rebecca, O'Brien, Susan M., and Jabbour, Elias

Published
2020
Full Text
View/download PDF

15. Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Author

Morita, Kiyomi, primary, Sasaki, Koji, additional, Richard-Carpentier, Guillaume, additional, Konopleva, Marina, additional, Huang, Xuelin, additional, Short, Nicholas J., additional, Jain, Nitin, additional, Ravandi, Farhad, additional, Dabaja, Bouthaina S., additional, Daver, Naval, additional, Kadia, Tapan M., additional, Alvarado, Yesid, additional, DiNardo, Courtney D., additional, Issa, Ghayas C., additional, Pemmaraju, Naveen, additional, Garcia-Manero, Guillermo, additional, Verstovsek, Srdan, additional, Wang, Sa A, additional, Khoury, Joseph D., additional, Jorgensen, Jeffrey L., additional, Champlin, Richard E., additional, Khouri, Issa F., additional, Kebriaei, Partow, additional, Schroeder, Heather M., additional, Khouri, Maria, additional, Takahashi, Koichi, additional, O'Brien, Susan M., additional, Kantarjian, Hagop M., additional, and Jabbour, Elias, additional

Published
2020
Full Text
View/download PDF

16. Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Richard-Carpentier, Guillaume, primary, Kantarjian, Hagop M., additional, Short, Nicholas J., additional, Ravandi, Farhad, additional, Ferrajoli, Alessandra, additional, Schroeder, Heather M, additional, Garcia-Manero, Guillermo, additional, Montalban Bravo, Guillermo, additional, Cortes, Jorge E., additional, Kwari, Monica, additional, Loiselle, Christopher, additional, Garris, Rebecca, additional, Volter, Nicole, additional, Jain, Nitin, additional, Konopleva, Marina Y, additional, Takahashi, Koichi, additional, Sasaki, Koji, additional, Wierda, William G., additional, and Jabbour, Elias, additional

Published
2019
Full Text
View/download PDF

17. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Richard-Carpentier, Guillaume, primary, Kantarjian, Hagop M., additional, Konopleva, Marina Y, additional, Patel, Keyur P., additional, Roberts, Kathryn G., additional, Gu, Zhaohui, additional, Ravandi, Farhad, additional, Jain, Nitin, additional, Short, Nicholas J., additional, Garcia-Manero, Guillermo, additional, Schroeder, Heather M, additional, Kwari, Monica, additional, Garris, Rebecca, additional, Khouri, Rita, additional, Jones, Mike, additional, Loiselle, Christopher, additional, Cortes, Jorge E., additional, Sasaki, Koji, additional, Issa, Ghayas C., additional, Kadia, Tapan M., additional, DiNardo, Courtney D., additional, Verstovsek, Srdan, additional, Daver, Naval G., additional, Mullighan, Charles G., additional, O'Brien, Susan M., additional, and Jabbour, Elias, additional

Published
2019
Full Text
View/download PDF

18. A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Richard-Carpentier, Guillaume, primary, Kantarjian, Hagop M., additional, Short, Nicholas J, additional, Ravandi, Farhad, additional, Ferrajoli, Alessandra, additional, Schroeder, Heather M, additional, Khouri, Maria, additional, Garcia-Manero, Guillermo, additional, Montalban Bravo, Guillermo, additional, Cortes, Jorge E., additional, Jain, Nitin, additional, Konopleva, Marina Y., additional, Takahashi, Koichi, additional, Sasaki, Koji, additional, Garris, Rebecca E., additional, and Jabbour, Elias J., additional

Published
2018
Full Text
View/download PDF

19. Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia.

Author

Maiti, Abhishek, primary, Kantarjian, Hagop M., additional, Ravandi, Farhad, additional, Thomas, Deborah A., additional, Khouri, Maria, additional, Garcia-Manero, Guillermo, additional, Garris, Rebecca S., additional, Cortes, Jorge E., additional, Short, Nicholas James, additional, Sasaki, Koji, additional, Issa, Ghayas C., additional, Koller, Paul B., additional, Schroeder, Heather M, additional, Kadia, Tapan M., additional, Verstovsek, Srdan, additional, Daver, Naval Guastad, additional, Jain, Nitin, additional, Konopleva, Marina, additional, O'Brien, Susan Mary, additional, and Jabbour, Elias, additional

Published
2017
Full Text
View/download PDF

21. Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

Author

Issa, Ghayas C., primary, Kantarjian, Hagop M., additional, Ravandi, Farhad, additional, Thomas, Deborah A., additional, Khouri, Maria, additional, Garcia-Manero, Guillermo, additional, Garris, Rebecca S., additional, Cortes, Jorge E., additional, Short, Nicholas James, additional, Sasaki, Koji, additional, Schroeder, Heather M, additional, Kadia, Tapan M., additional, Verstovsek, Srdan, additional, Daver, Naval Guastad, additional, Jain, Nitin, additional, Konopleva, Marina, additional, O'Brien, Susan Mary, additional, and Jabbour, Elias, additional

Published
2016
Full Text
View/download PDF

22. Timing the Mode Switch in a Sequential Mixed-Mode Survey.

Author

Wagner, James, Schroeder, Heather M., Piskorowski, Andrew, Heeringa, Steven G., Ursano, Robert J., Stein, Murray B., and Colpe, Lisa J.

Subjects
*TELEPHONE surveys, *RESPONSE rates, *SURVEYS, *MENTAL health, *SAMPLING (Process)
Abstract

Mixed-mode surveys need to determine a number of design parameters that may have a strong influence on costs and errors. In a sequential mixed-mode design with web followed by telephone, one of these decisions is when to switch modes. The web mode is relatively inexpensive but produces lower response rates. The telephone mode complements the web mode in that it is relatively expensive but produces higher response rates. Among the potential negative consequences, delaying the switch from web to telephone may lead to lower response rates if the effectiveness of the prenotification contact materials is reduced by longer time lags, or if the additional e-mail reminders to complete the web survey annoy the sampled person. On the positive side, delaying the switch may decrease the costs of the survey. We evaluate these costs and errors by experimentally testing four different timings (1, 2, 3, or 4 weeks) for the mode switch in a web–telephone survey. This experiment was conducted on the fourth wave of a longitudinal study of the mental health of soldiers in the U.S. Army. We find that the different timings of the switch in the range of 1–4 weeks do not produce differences in final response rates or key estimates but longer delays before switching do lead to lower costs. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

23. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial

Author

Maiti, Abhishek, Kantarjian, Hagop M., Ravandi, Farhad, Khouri, Maria, Thomas, Deborah A, Garcia-Manero, Guillermo, Garris, Rebecca, Cortes, Jorge E., Short, Nicholas J, Jain, Nitin, Bose, Prithviraj, Verstovsek, Srdan, Konopleva, Marina, Sasaki, Koji, Issa, Ghayas C., Ghosn, Marie, Schroeder, Heather M, Kadia, Tapan, Daver, Naval, O'Brien, Susan M., and Jabbour, Elias J.

Abstract

Background:Chemoimmunotherapy is standard frontline therapy for acute lymphoblastic leukemia (ALL). Rituximab (R) added to hyper-CVAD (HCVAD) has been shown to improve complete remission duration (CRD) and overall survival (OS) in patients (pts) with CD20-positive ALL with ≥20% CD20 expression. Ofatumumab (O) is a type I human antibody that binds to a distinct CD20 epitope compared to rituximab, and induces more potent antibody-dependent and complement mediated cytotoxicity in vitro. We hypothesized that combining ofatumumab with HCVAD may improve outcomes in CD20+ ALL.

Published
2017
Full Text
View/download PDF

24. Measuring Early Relational Health Using PediaTrac TM in a Diverse Sample of Infant-Caregiver Dyads.

Author

Huth-Bocks A, Franz S, Berglund PA, Schroeder HM, Staples AD, Raghunathan T, Warschausky S, Taylor HG, LeDoux G, Dieter L, Rosenblum K, and Lajiness-O'Neill R

Subjects
Humans, Female, Infant, Male, Parent-Child Relations, Caregivers, Infant, Newborn, Adult, Infant, Premature physiology, Child Development physiology, Reproducibility of Results, Psychometrics standards, Psychometrics instrumentation
Abstract

Objective: Early relational health (ERH) is a key developmental predictor and outcome in infancy and early childhood that reflects social-emotional well-being and promotes resilience throughout childhood. Currently, there is no gold-standard developmental screening tool for ERH in pediatric care settings. This study examined the psychometric properties of items assessing ERH that are part of a web-based, caregiver-report screening tool called PediaTrac TM . It was hypothesized that ERH could be reliably estimated and that second-order factors would be revealed within the latent construct ERH., Method: Participants included 571 caregivers of term (n = 331; ≥37 weeks) and preterm (n = 240; <37 weeks) infants recruited shortly after birth from several academic medical centers and a community health clinic. Caregivers completed PediaTrac modules at birth and 2, 4, 6, 9, 12, 15, and 18 months; data for this study are from the newborn through 12-month periods., Results: Results from Item Response Theory Graded Response Modeling revealed excellent reliability for the PediaTrac ERH domain at all time points, ranging from 0.96 to 0.98. Exploratory factor analyses revealed 4 to 5 second-order factors, representing Parent-Child Relationship, Parent Distress, Parenting Stress, Parenting Efficacy, Sensitivity, and Perceptions of Child, depending on period., Conclusion: The caregiver-report developmental screening tool, PediaTrac, reliably measures ERH during the first year of life. The measure has promising clinical utility in pediatric clinic settings for tracking ERH over time to ensure early social-emotional well-being and to identify concerns as early as possible., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

25. Forced Intercourse in America: A Pandemic Update.

Author

Axinn WG, West BT, and Schroeder HM

Abstract

Background : Measures of forced intercourse from the U.S. National Center for Health Statistics (NCHS) indicate this a high prevalence among U.S. women that is likely to produce unintended pregnancies. However, NCHS did not measure forced intercourse during the pandemic, limiting knowledge of recent prevalence rates. Methods : We use multiple nationally-representative, cross-sectional surveys representing the U.S. population from 2011 to 2022 to document these trends. This includes measures from the National Survey of Family Growth, the Panel Study of Income Dynamics Transition into Adulthood Supplement, and the American Family Health Study (AFHS) to provide population estimates of forced intercourse. Results : Reports of forced intercourse remained high during the pandemic, with more than 25% of U.S. females over 40 reporting lifetime forced intercourse in the AFHS (number of females in AFHS: 1,042). There was a significant increase among females aged 24-28 (p<.05) and rates are highest for those who did not complete college. Among females 24-28, 32.5% (S.E. = 5.7%) with less than 4 years of college reported forced intercourse, a significantly (p<.05) higher rate than among those with higher education. Conclusions : Rates of forced intercourse among U.S. women remained high during the pandemic, increasing significantly in early adulthood. This exposure to forced intercourse is likely to produce an increase in unintended pregnancies and other sexual, reproductive, and mental health problems.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results